IDRx Stock

idrx.comHealthcare / BioTech & PharmaFounded: 2021Funding to Date: $242.24MM

IDRx is a clinical-stage biopharmaceutical company that offers precision therapies to patients with gastrointestinal stromal tumors (GIST). Their pipeline includes small molecule tyrosine kinase inhibitors, IDRX-42 and IDRX-73, designed to target genetic drivers and drug-resistant mutations in GIST. IDRx aims to explore the potential of highly potent and selective therapies to address treatment limitations in precision cancer medicine. This company was founded by Alexis Borisy, Ben Auspitz, George Demetri MD, Nicholas Lydon Ph.D, and Robert Forrester in 2021 and is headquartered in Plymouth, MA.

Register To Buy and Sell Private Company Shares

For more details on private stock price information, financing and valuation for IDRx, register or login.
Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Private Market Pricing DetailsValuation & Financings

IDRx Stock Price

Forge Price 1
Price not yet available
Last Closed Trade 2
Close Date
xx/xx/xx
Last Closed Trade Price
$xx.xx
Last Funding Round (LFR)
Date
xx/xx/xx
Price per Share
$xx.xx

IDRx Funding Rounds and Valuation

Funding History Chart
Funding Round Details
Funding Date Share Class Amount Raised Price per Share Post-Money Valuation Key Investors
08/07/2024 Series B $120.24MM $xx.xx $414.65MM RA Capital Management, Commodore Capital, Blackstone, Rock Springs Capital, Andreessen Horowitz, Forge Life Science Partners, Nick Lydon, Merck, Nextech Invest
Price per Share
$xx.xx
Shares Outstanding
18,667,528
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
RA Capital Management, Commodore Capital, Blackstone, Rock Springs Capital, Andreessen Horowitz, Forge Life Science Partners, Nick Lydon, Merck, Nextech Invest
08/02/2022 Series A-2 $16.19MM $xx.xx $309.5MM Andreessen Horowitz, Casdin Capital, Nextech Invest, Forge Life Science Partners, Blueprint Medicines
Price per Share
$xx.xx
Shares Outstanding
2,947,184
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Andreessen Horowitz, Casdin Capital, Nextech Invest, Forge Life Science Partners, Blueprint Medicines
08/02/2022 Series A-1 $105.81MM $xx.xx $309.5MM Andreessen Horowitz, Casdin Capital, Nextech Invest, Forge Life Science Partners, Blueprint Medicines
Price per Share
$xx.xx
Shares Outstanding
17,333,480
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Andreessen Horowitz, Casdin Capital, Nextech Invest, Forge Life Science Partners, Blueprint Medicines

IDRx investors also invested in these private companies

IDRx stock FAQs

plusminus

Can you buy IDRx stock?

As IDRx is not publicly traded, purchasing its stock is not available to everyone. To buy the stock of a private companies like IDRx, you must be an accredited investor. If you meet the accreditation criteria, you can register for Forge’s Secondary Marketplace to buy private market stock. If you are not accredited, find out how to begin the process and qualify for new investment opportunities.
plusminus

How to buy IDRx stock?

To invest in a private company like IDRx through Forge, you must first qualify as an accredited investor. (Learn more about the accreditation process.)

  1. Create a free account to access Forge’s marketplace.
  2. Express your interest in specific investments. Within Forge Markets, you will find detailed pricing and financing information for thousands of private companies.
  3. Throughout this process, a dedicated Forge Private Market Specialist will be available to address any questions you may have and to guide you seamlessly through each step of the transaction.
plusminus

Can you sell IDRx stock?

Yes, you may sell the IDRx stock you currently own. Forge can help you facilitate the sale of your stock in a manner that aligns with your needs and the company’s interests. If you are looking for liquidity, register with us today to begin the process. A dedicated Forge Private Market Specialist will be available to address any questions you may have along the way.
plusminus

How to sell IDRx stock?

If you hold private company shares of IDRx – whether as an employee or an early investor – Forge can help you sell them.

  1. Create a free Forge account, this will give you access to Forge’s marketplace and to one of our experienced Private Market Specialist to answer any questions you might have.
  2. Indicate your interest to sell your IDRx on our platform.
  3. Work with your dedicated Private Market Specialist who’ll help guide you through every step of the transaction.
plusminus

Is IDRx a public company?

No, IDRx is a privately held company and is currently not publicly traded on any stock markets including NYSE or NASDAQ.
plusminus

What is IDRx’s stock price?

IDRx is a privately held company and therefore does not have a public stock price. However, you may access IDRx private market stock price with Forge Data.
plusminus

What is IDRx’s stock ticker symbol?

IDRx does not have an official ticker symbol because this company is not currently publicly traded.
plusminus

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

IDRx’s news and media highlights

Biopharmaceutical startup IDRx raised $120 million in a Series B funding round led by RA Capital, Commodore Capital, and Blackstone. The company plans to use the funds to accelerate development of its cancer therapy drug candidate IDRX-42 and initiate a proposed pivotal study for second-line GIST treatment.
Precision therapeutics company IDRx has raised $120 million in Series B financing to fund clinical trials for its lead oncology candidate IDRX-42, a tyrosine kinase inhibitor licensed from Merck KGaA. The funding will support Phase I and pivotal trials evaluating IDRX-42 for treating gastrointestinal stromal tumors.
Biopharma companies Sumitomo, Kineta, IDRx, and others made executive appointments and restructurings. Sumitomo promoted an executive as part of restructuring that includes job cuts. Kineta halted a trial and cut most staff as it considers sale. IDRx hired two executives from Theseus. The moves come amid a period of change for biopharmas.
Updated on: Nov 21, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

1. Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price may rely on a very limited number of inputs in its calculation. Forge Price is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price. Forge Price is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge.  Forge Price is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

2. The Last Closed Trade price displayed reflects the price at which the last trade in this company's security occurred on Forge, and can include secondary trades in any class of the company's security, or trades in units of funds holding the company's securities (the economics of which differ versus direct company ownership). The date displayed reflects the date on which the last trade in this company's security closed on Forge. This may be several weeks after the terms of the trade were agreed upon between the buyer and seller. In case of multiple trades closed on the same date, the price displayed is of either (i) the trade which terms were agreed upon most recently; or (ii) the trade with the higher notional value.

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.